CD22 and acute lymphoblastic leukemia: After administration of Besponsa®, the anti-CD22 monoclonal antibody binds to CD22 on B cells in B-ALL and is internalized into the cell, where the hydrazone linker undergoes hydrolysis to release calicheamicin, which causes DNA damage and cell death [11,12].